What is the purpose of the Bortezomib 2mg injection?
The medication Bortezomib 2mg is used to treat multiple myeloma, a type of cancer of the bone marrow. Bortezomib is also used to treat patients with mantle cell lymphoma, fast-growing cancer that begins in the cells of the immune system. Bortezomib is an antineoplastic agent, which means it fights cancer.
Is bortezomib a type of chemotherapy?
Velcade (bortezomib) is a targeted therapy, which is a kind of chemotherapy. Velcade is a proteasome inhibitor, which is a type of medication. The FDA has given it the approval to treat multiple myeloma and mantle cell lymphoma. Many notable clinical trials have looked into VELCADE.
What is the most extreme measure of time you can take bortezomib?
In the event that you’ve proactively gotten myeloma treatment, you can have bortezomib all by yourself. Bortezomib is commonly taken twice a week for two weeks. After that, you get a ten-day rest. A treatment cycle is a three-week time of treatment.
What are the Bortezomib 2mg side effects?
- loss of appetite
- or pain/redness may occur at the injection site. Queasiness,
- and loose bowels are generally normal aftereffects.
- Your primary care physician might prescribe a prescription to forestall or lighten sickness
- regurgitation, or the runs in certain conditions.
For more details Click Here.
Is Bortezomib 2mg associated with hair loss?
Hair loss is a common occurrence. Hair loss isn’t a direct side effect of Velcade, but it could be caused by other medications you’re taking with it. People using Velcade plus the cytotoxic medication cyclophosphamide, for example, may experience hair loss.
How is Bortezomib 2mg administered?
Bortezomib 1 mg powder for solution for injection is given intravenously twice weekly for two weeks at a dose of 1.3 mg/m2 of body surface area on days 1, 4, 8, and 11 of a 21-day treatment cycle. A treatment cycle is defined as a three-week period.
Is Bortezomib 2mg an oral medication?
As per information from a mid-stage study introduced at the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia, the investigational oral proteasome inhibitor MLN9708—which is a new version of Velcade® (bortezomib)—may be more effective and well-tolerated than Velcade injections.
What is the composition of bortezomib?
Bortezomib is l-phenylalaninamide with a 1-(dihydroxyboranyl)-3-methylbutyl group at the amide nitrogen and a pyrazin-2-ylcarbonyl group at N(alpha). It’s a dipeptidyl boronic acid that inhibits the 26S proteasome in a reversible manner.